Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 304
6
Diseases
302
Unique genes
0.214
Avg. similarity score
Non-neoplastic peripheral nervous system disease
Most-connected disease (4 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Non-neoplastic peripheral nervous system disease
Peripheral nervous system disease
Nervous system disease
Charcot-Marie-Tooth disease axonal type 2CC
Peripheral neuropathy
Bell's palsy
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Non-neoplastic peripheral nervous system disease | 4 | 4 | 54 |
| Peripheral nervous system disease | 4 | 4 | 53 |
| Nervous system disease | 3 | 3 | 68 |
| Charcot-Marie-Tooth disease axonal type 2CC | 2 | 2 | 1 |
| Peripheral neuropathy | 2 | 2 | 192 |
| Bell's palsy | 1 | 1 | 56 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| ABCB1 | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ATF3 | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CASP9 | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CSF3 | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CYP2C8 | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| DPYD | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| GFAP | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| NEFH | 4 / 6 | Charcot-Marie-Tooth disease axonal type 2CC, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| NGF | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| PNPLA6 | 4 / 6 | Nervous system disease, Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ABCA1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ABCC1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ALOX12 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CACNA1B | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CACNA1H | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CDKN2A | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CPT1C | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CTLA4 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| DAPK1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| DYNC1I1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ERCC1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ERCC3 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ERCC4 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| GAN | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| GJB3 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| GJE1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| GLI1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| GSTP1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| ICAM1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| IGF1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| IGF1R | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| IL6 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| JUN | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| MBL2 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| MKI67 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| MMP3 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| MYO5A | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| MYOT | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| NPY | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| PMP22 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| PPARD | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| PRKCE | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| PSMB1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| RHOBTB2 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| SERPINB2 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| SLC12A6 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| SOD2 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| SOX8 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| TCF4 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| TNFRSF10A | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| UCHL1 | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| XK | 3 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral nervous system disease, Peripheral neuropathy |
| CDC5L | 2 / 6 | Bell's palsy, Nervous system disease |
| FARP1 | 2 / 6 | Bell's palsy, Nervous system disease |
| GPC6 | 2 / 6 | Nervous system disease, Peripheral neuropathy |
| GRIK2 | 2 / 6 | Bell's palsy, Nervous system disease |
| GSTT1 | 2 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral neuropathy |
| ND1 | 2 / 6 | Non-neoplastic peripheral nervous system disease, Peripheral neuropathy |
| SLC2A1 | 2 / 6 | Bell's palsy, Nervous system disease |
| SUPT3H | 2 / 6 | Bell's palsy, Nervous system disease |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Antifolate resistance | KEGG | 11 / 30 | 14.6× | 7.57e-11 | 1.12e-8 ✓ sig. |
| Folate transport and metabolism | KEGG | 8 / 31 | 10.3× | 6.95e-7 | 3.55e-5 ✓ sig. |
| Lipid and atherosclerosis | KEGG | 17 / 216 | 3.1× | 3.21e-5 | 8.84e-4 ✓ sig. |
| Caspase activation via Dependence Receptors in the absence of ligand | Reactome | 3 / 4 | 29.8× | 6.18e-5 | 1.52e-3 ✓ sig. |
| Platinum drug resistance | KEGG | 9 / 75 | 4.8× | 1.04e-4 | 2.33e-3 ✓ sig. |
| Viral protein interaction with cytokine and cytokine receptor | KEGG | 10 / 100 | 4.0× | 2.04e-4 | 3.97e-3 ✓ sig. |
| Pathways in cancer | KEGG | 27 / 533 | 2.0× | 4.27e-4 | 7.04e-3 ✓ sig. |
| Pathways of neurodegeneration - multiple diseases | KEGG | 25 / 480 | 2.1× | 4.65e-4 | 7.53e-3 ✓ sig. |
| IL-17 signaling pathway | KEGG | 9 / 94 | 3.8× | 5.83e-4 | 8.99e-3 ✓ sig. |
| Apoptosis | KEGG | 11 / 137 | 3.2× | 6.74e-4 | 1.01e-2 ✓ sig. |
| Metabolism of folate and pterines | Reactome | 4 / 17 | 9.4× | 7.20e-4 | 1.06e-2 ✓ sig. |
| TNF signaling pathway | KEGG | 10 / 119 | 3.3× | 8.26e-4 | 1.18e-2 ✓ sig. |
| ABC transporters | KEGG | 6 / 45 | 5.3× | 8.58e-4 | 1.21e-2 ✓ sig. |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | Reactome | 3 / 10 | 11.9× | 1.66e-3 | 1.99e-2 ✓ sig. |
| Chemical carcinogenesis - DNA adducts | KEGG | 7 / 70 | 4.0× | 1.83e-3 | 2.14e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| response to hypoxia | GO:0001666 | 16 / 176 | 5.6× | 2.86e-8 | 4.22e-6 ✓ sig. |
| positive regulation of apoptotic process | GO:0043065 | 20 / 326 | 3.8× | 3.84e-7 | 3.75e-5 ✓ sig. |
| xenobiotic transport across blood-brain barrier | GO:1990962 | 4 / 6 | 41.3× | 9.78e-7 | 8.14e-5 ✓ sig. |
| cellular response to amyloid-beta | GO:1904646 | 8 / 53 | 9.3× | 2.00e-6 | 1.44e-4 ✓ sig. |
| response to xenobiotic stimulus | GO:0009410 | 16 / 248 | 4.0× | 3.00e-6 | 1.99e-4 ✓ sig. |
| replicative senescence | GO:0090399 | 5 / 16 | 19.3× | 4.03e-6 | 2.53e-4 ✓ sig. |
| neurofilament bundle assembly | GO:0033693 | 3 / 3 | 61.9× | 4.18e-6 | 2.60e-4 ✓ sig. |
| negative regulation of collagen biosynthetic process | GO:0032966 | 5 / 17 | 18.2× | 5.63e-6 | 3.30e-4 ✓ sig. |
| positive regulation of neuron apoptotic process | GO:0043525 | 8 / 65 | 7.6× | 9.63e-6 | 5.06e-4 ✓ sig. |
| response to ethanol | GO:0045471 | 10 / 110 | 5.6× | 1.18e-5 | 5.93e-4 ✓ sig. |
| export across plasma membrane | GO:0140115 | 4 / 10 | 24.8× | 1.30e-5 | 6.42e-4 ✓ sig. |
| neurofilament cytoskeleton organization | GO:0060052 | 4 / 10 | 24.8× | 1.30e-5 | 6.42e-4 ✓ sig. |
| cellular response to hypoxia | GO:0071456 | 11 / 139 | 4.9× | 1.63e-5 | 7.68e-4 ✓ sig. |
| positive regulation of smooth muscle cell proliferation | GO:0048661 | 7 / 52 | 8.3× | 1.93e-5 | 8.72e-4 ✓ sig. |
| tetrahydrofolate metabolic process | GO:0046653 | 4 / 11 | 22.5× | 2.02e-5 | 9.04e-4 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Non-neoplastic peripheral nervous system disease | Peripheral nervous system disease | 0.929 | 52 | 1.19e-145 | 2.22e-143 ✓ sig. |
| Non-neoplastic peripheral nervous system disease | Peripheral neuropathy | 0.280 | 54 | 4.24e-107 | 5.74e-105 ✓ sig. |
| Peripheral nervous system disease | Peripheral neuropathy | 0.268 | 52 | 2.70e-101 | 3.26e-99 ✓ sig. |
| Nervous system disease | Peripheral nervous system disease | 0.080 | 9 | 1.40e-12 | 1.77e-11 ✓ sig. |
| Nervous system disease | Non-neoplastic peripheral nervous system disease | 0.079 | 9 | 1.68e-12 | 2.07e-11 ✓ sig. |
| Bell's palsy | Nervous system disease | 0.042 | 5 | 4.64e-6 | 2.56e-5 ✓ sig. |
| Charcot-Marie-Tooth disease axonal type 2CC | Peripheral nervous system disease | 0.019 | 1 | 3.44e-3 | 4.44e-3 ✓ sig. |
| Charcot-Marie-Tooth disease axonal type 2CC | Non-neoplastic peripheral nervous system disease | 0.018 | 1 | 3.51e-3 | 4.51e-3 ✓ sig. |